

The role of Bcl-2 in controlling the transition between autophagy and apoptosis (Review)

AHMET ALPEREN PALABIYIK

Department of Nursing, Faculty of Health Sciences, Ardahan University, Çamlıçatak, Ardahan 75002, Turkey

Received December 23, 2024; Accepted April 1, 2025

DOI: 10.3892/mmr.2025.13537

Abstract. The Bcl-2 protein family serves a key role in maintaining cellular homeostasis by regulating the balance between autophagy and apoptosis. The present review aimed to summarize interactions of Bcl-2 with key proteins, including Beclin 1, Bax and Bcl-2 homologous antagonist/killer, as well as its influence on cellular processes such as mitophagy, nutrient sensing and endoplasmic reticulum stress response. The impact of post-translational modifications of Bcl-2, including phosphorylation, ubiquitination and sumoylation, is discussed with respect to their regulatory roles under stress. In pathological states, Bcl-2 upregulation in cancer suppresses apoptosis and autophagy, thereby facilitating tumor survival and resistance to chemotherapy. Conversely, in neurodegenerative diseases, impaired autophagy and increased apoptosis contribute to neuronal loss. Therapeutic strategies targeting Bcl-2 (for example inhibitors such as venetoclax, navitoclax, obatoclax and combination therapies involving autophagy modulators) were evaluated for their potential efficacy. There is lack of understanding of tissue-specific functions of Bcl-2 and its interactions with non-coding RNAs. Future research should prioritize these areas and leverage advanced single-cell technologies to elucidate the real-time dynamics of Bcl-2 in cell processes. The present review highlights the key role of Bcl-2 in cell fate determination and highlights its potential as a therapeutic target, offering insight for the development of innovative treatments for cancer, neurodegenerative disorder and age-related diseases.

Contents

1. Introduction
2. Database search

3. Mechanisms of Bcl-2 in regulating autophagy
4. Role of Bcl-2 in apoptosis
5. Interplay between autophagy and apoptosis
6. Therapeutic implications
7. Research gaps and future directions
8. Conclusion

1. Introduction

The Bcl-2 protein family constitutes a key group of regulators that maintain cellular homeostasis by modulating both autophagy and apoptosis (1). This family is classified into anti-apoptotic proteins, including Bcl-2, Bcl-xl and myeloid cell leukemia 1 (Mcl-1), and pro-apoptotic proteins, such as Bax, Bcl-2 homologous antagonist/killer (Bak) and BH3 interacting-domain death agonist (2) (Table I). This classification underscores their opposing roles in cell survival and programmed cell death. Anti-apoptotic proteins inhibit mitochondrial outer membrane permeabilization (MOMP) and suppress caspase activation, thereby preventing apoptosis. By contrast, pro-apoptotic proteins promote MOMP and facilitate apoptotic cascades, leading to cell death. The dynamic equilibrium between these determines cellular fate under stress conditions (3-6).

Autophagy and apoptosis are key for cellular integrity. Autophagy, a catabolic pathway, degrades and recycles damaged organelles and misfolded proteins to sustain cell energy levels and homeostasis (7,8). Conversely, apoptosis eliminates irreversibly damaged or dysfunctional cells, thereby preventing harm to the organism (9,10). While these processes are distinct, they share regulatory molecules, including Bcl-2 family proteins, and their interplay is key for cell decision-making under stress conditions (11).

The role of Bcl-2 is multifaceted. Bcl-2 inhibits autophagy by binding to Beclin 1, a key autophagy regulator, thereby suppressing autophagic flux initiation. Simultaneously, it prevents apoptosis by interacting with pro-apoptotic proteins such as Bax and Bak. However, under severe or prolonged stress, post-translational modifications (PTMs), including phosphorylation, may disrupt these interactions, shifting the balance toward either autophagy or apoptosis (12-14). Dysregulation of Bcl-2-mediated pathways is implicated in various pathological conditions: In cancer, Bcl-2 upregulation enhances tumor survival by preventing apoptosis

Correspondence to: Dr Ahmet Alperen Palabiyik, Department of Nursing, Faculty of Health Sciences, Ardahan University, Yenisey Campus, Çamlıçatak, Ardahan 75002, Turkey
E-mail: ahmetalperenpalabiyik@ardahan.edu.tr

Key words: Bcl-2, autophagy, apoptosis, Beclin 1, mitophagy

and suppressing autophagy, contributing to chemotherapy resistance (15). Conversely, in neurodegenerative disorders, impaired regulation of autophagy and apoptosis accelerates neuronal loss. These pathological contexts highlight the key role of Bcl-2 in coordinating the transition between autophagy and apoptosis (16,17).

The present review aimed to provide a comprehensive analysis of the mechanisms by which Bcl-2 regulates autophagy and apoptosis. By examining its molecular interactions, pathological implications and potential as a therapeutic target, the present review aimed to elucidate the central role of Bcl-2 in cellular homeostasis and disease pathogenesis.

2. Database search

The present review was conducted through a systematic literature search in PubMed (pubmed.ncbi.nlm.nih.gov/), Google Scholar (scholar.google.com/) and Web of Science (<https://www.webofscience.com/wos/>). The search covered publications from January 2014 to December 2024. The following search terms were: 'Bcl-2 AND autophagy', 'Bcl-2 AND apoptosis', 'Bcl-2 AND Beclin 1', 'Bcl-2 AND mitophagy', 'Bcl-2 AND cancer resistance', 'Bcl-2 AND neurodegeneration', 'Bcl-2 inhibitors AND therapy' and 'Bcl-2 AND post-translational modifications'. Only peer-reviewed articles published in English were selected. Eligible studies included review articles and preclinical and clinical studies; non-peer-reviewed sources (for example, preprints, conference abstracts, editorials) and articles without a primary focus on Bcl-2 regulatory functions were excluded. Reference lists of studies were manually searched to identify additional relevant literature that may have been missed in the initial search.

3. Mechanisms of Bcl-2 in regulating autophagy

Bcl-2 and autophagy regulation. Bcl-2 regulates autophagy through its interactions with Beclin 1 and mitochondrial quality control mechanisms (18). The inhibition of autophagy by Bcl-2 primarily occurs via direct binding to the BH3 domain of Beclin 1, a key autophagy regulator (13). This interaction prevents Beclin 1 from initiating autophagosome formation, thereby restricting autophagic activity under physiological conditions (14). However, under metabolic or oxidative stress, PTMs, such as phosphorylation at serine 70 (Ser70), disrupt this interaction, enabling Beclin 1 to activate autophagy (19-21) (Fig. 1).

Bcl-2 regulates mitophagy, the selective degradation of dysfunctional mitochondria. It modulates MOMP, thereby controlling the release of mitochondrial quality control factors such as PTEN-induced kinase 1 and Parkin (22,23). These proteins coordinate mitochondrial tagging for degradation, ensuring the elimination of damaged mitochondria while preventing excessive mitophagy, which could compromise cellular bioenergetics (24).

This dual regulatory function positions Bcl-2 as a key integrator of cellular stress signals (Fig. 2). Under nutrient deprivation, AMPK activation phosphorylates Bcl-2, leading to its dissociation from Beclin 1, facilitating autophagy (25,26). Conversely, under nutrient-rich conditions, mTOR activation stabilizes the Bcl-2-Beclin 1 complex, thereby inhibiting

autophagy and promoting cell survival. Furthermore, oxidative stress-induced phosphorylation of Bcl-2 determines whether the balance shifts toward autophagy or apoptosis (27,28).

PTMs of Bcl-2. PTMs of Bcl-2 serve a key role in modulating its interactions and function, allowing for precise regulation of autophagy and apoptosis. Phosphorylation at residues such as Ser70 enhances dissociation of Bcl-2 from Beclin 1, thereby promoting autophagy in response to stress, including nutrient deprivation or oxidative damage. Conversely, phosphorylation at alternative sites may stabilize interactions of Bcl-2 with pro-apoptotic proteins, further suppressing apoptosis (29,30).

Caspase-mediated cleavage of Bcl-2 during apoptosis is another key PTM, converting Bcl-2 from an anti-apoptotic protein into a pro-apoptotic fragment that amplifies apoptotic signaling (31,32). Additionally, ubiquitination regulates proteasomal degradation of Bcl-2, influencing its intracellular levels and functional activity. Sumoylation and acetylation are key PTMs that modulate interactions of Bcl-2 with mitochondrial and cytosolic targets, further underscoring the complexity and context-dependent nature of its regulation (33-35) (Fig. 3).

Role of Bcl-2 in nutrient sensing and metabolic regulation. Bcl-2 serves a key role in nutrient sensing and metabolic regulation. Through its interactions with the mTOR and AMPK pathways, Bcl-2 enables cell adaptation to nutrient deprivation by modulating autophagy (36). During starvation, AMPK activation phosphorylates Bcl-2, weakening its interaction with Beclin 1 and enhancing autophagy to sustain energy production and preserve cellular integrity (37). This phosphorylation also facilitates the redistribution of autophagic machinery components to damaged or stressed cell regions, ensuring a targeted autophagic response.

Conversely, under nutrient-rich conditions, mTOR signaling suppresses autophagy, with Bcl-2 contributing to this suppression by stabilizing Beclin 1 in an inactive state and reinforcing cell proliferation pathways (38,39). Additionally, Bcl-2 serves a role in modulating lysosomal function during autophagy, ensuring the efficient degradation and recycling of cellular components. This multifaceted regulatory function underscores the key role of Bcl-2 in maintaining metabolic homeostasis and dynamically responding to fluctuating nutrient levels (26,40,41).

Bcl-2 in endoplasmic reticulum (ER) stress and unfolded protein response (UPR). Under ER stress, Bcl-2 serves a key role in modulating the UPR, an important mechanism for cell adaptation to misfolded protein accumulation (42). At ER-mitochondria contact sites, Bcl-2 regulates calcium signaling by controlling calcium release from the ER to mitochondria, which is key for both ATP production and apoptosis regulation (43). Dysregulated calcium transfer can result in mitochondrial calcium overload, triggering pro-apoptotic pathways.

Prolonged ER stress compromises the anti-apoptotic functions of Bcl-2 by altering its interactions with proteins at contact sites. Additionally, Bcl-2 directly modulates UPR pathways through interactions with key mediators such as inositol-requiring enzyme 1 and protein kinase R-like ER kinase, thereby influencing the cell fate between adaptive recovery and apoptotic cell death. Bcl-2 also contributes to

Table I. Family members of Bcl-2.

Effect on apoptosis	Protein		Function	Key interactions
Anti-apoptotic	Bcl-2		Inhibits apoptosis, promotes cell survival	Bax, Bak, Beclin 1
	Bcl-xl		Prevents apoptosis, maintains mitochondrial integrity	Bax, Bak, Bad
	Mcl-1		Supports cell survival	Bax, Bak, BH3-only proteins
	Bcl-w		Inhibits apoptosis, supports neuronal survival	Bax, Bak
Pro-apoptotic	A1/Bfl-1		Promotes cell survival, especially in immune cells	
	Multi domain	Bax	Oligomerizes in the cytosol upon activation, translocates to mitochondria to induce MOMP and initiate apoptosis	Bcl-2, Bcl-xl, Bak
		Bak	Constitutively anchored in the mitochondrial membrane; triggers MOMP upon activation and promotes apoptosis in cooperation with Bax	Bcl-2, Bcl-xl, Bax
	BH3 only	Bid	Activates Bax and Bak, promotes apoptosis	Bcl-2, Bcl-xl
		Bim	Activates Bax and Bak, inhibits Bcl-2 and Bcl-xl	
		Bad	Interacts with anti-apoptotic proteins to promote apoptosis	
		Noxa	Targets Mcl-1 for degradation, induces apoptosis	Mcl-1
		Puma	Inhibits Bcl-2 family proteins, induces apoptosis	Bcl-2, Bcl-xl, Mcl-1
		BNip3	Regulates autophagy and apoptosis	Beclin 1, Bcl-2
		Bik	Promotes apoptosis by interacting with anti-apoptotic proteins	Bcl-2, Bcl-xl

Mcl-1, myeloid cell leukemia 1; Bak, Bcl-2 homologous antagonist/killer; Bid, BH3-interacting domain death agonist; Bim, Bcl-2-interacting mediator of cell death; MOMP, mitochondrial outer membrane permeabilization; Bad, Bcl-2-associated death promoter; Bik, Bcl-2-interacting killer; Puma, p53 upregulated modulator of apoptosis; BNip3, Bcl-2/adenovirus E1B 19 kDa-interacting protein 3.

stabilizing mitochondrial membrane potential during ER stress, further underscoring its multifaceted role in maintaining cell homeostasis under adverse conditions (44-46).

Bcl-2 in immune cell regulation. Bcl-2 is key for the survival and function of immune cells, including T and B lymphocytes. By inhibiting apoptosis, Bcl-2 promotes the longevity of memory T cells, which are key for maintaining immune memory and facilitating rapid secondary responses to antigens (47). Additionally, it supports the development of germinal center B cells, enabling effective antibody diversification and maturation.

Dysregulation of Bcl-2 in immune cells is associated with pathologies, including autoimmune disease, where excessive survival of autoreactive lymphocytes exacerbates immune responses, and lymphoproliferative disorders, which are characterized by uncontrolled immune cell proliferation (48,49). Beyond its role in apoptosis regulation, Bcl-2 also modulates autophagy within immune cells, aiding adaptation to metabolic and environmental stress. This dual function in apoptosis inhibition and autophagy regulation enables immune cells to sustain functionality during nutrient deprivation or infection, ensuring a robust and persistent immune response (50,51).

Bcl-2 in aging and cellular senescence. Aging and cellular senescence are associated with alterations in the regulation

of autophagy and apoptosis, reflecting a decline in the efficiency of cell stress response mechanisms. The expression and activity of Bcl-2 decrease with age, which can impair mitochondrial quality control and lead to the accumulation of damaged organelles (52,53). This contributes to increased oxidative stress, as reactive oxygen species are no longer effectively neutralized, thereby exacerbating age-associated pathologies such as neurodegeneration, cardiovascular disease and metabolic disorders. In senescent cells, the altered function of Bcl-2 not only affects autophagic flux but also disrupts the balance between cell survival and programmed cell death, resulting in chronic inflammation and tissue dysfunction (54,55). Therapeutic strategies (such as BH3 mimetics, Bcl-2 inhibitors, caloric restriction mimetics, or gene therapy approaches) targeting Bcl-2 in aging aim to restore the balance between autophagy and apoptosis by enhancing mitochondrial turnover, decreasing oxidative damage and promoting tissue regenerative capacity. These interventions may mitigate age-associated functional decline and enhance cell resilience in aging populations (56,57).

4. Role of Bcl-2 in apoptosis

Inhibition of pro-apoptotic proteins. Bcl-2 inhibits apoptosis by binding pro-apoptotic proteins such as Bax and Bak, thereby preventing MOMP and the subsequent release of cytochrome




Figure 1. Role of the Bcl-2 protein family in regulating apoptosis. Bcl-2 family regulates cell survival or death. BH3-only proteins (Bim, Bad, Puma) interact with and inhibit anti-apoptotic proteins (Bcl-2, Bcl-xL), enabling activation of pro-apoptotic effector proteins (Bax and Bak). These proteins facilitate MOMP by forming pores in the mitochondrial outer membrane. This results in the release of cytochrome c, which binds apoptotic protease activating factor-1 and activates the apoptosome, ultimately leading to apoptosis. MOMP, mitochondrial outer membrane permeabilization; BH3-only, Bcl-2 homology 3-only; Bcl-w, Bcl-2-like protein W; Mcl-1, myeloid cell leukemia 1; A1, Bcl-2-related protein A1; Bok, Bcl-2-related ovarian killer; Bim, Bcl-2-like protein 11; Bad, Bmf, Bcl-2-modifying factor; Bik, Bcl-2 interacting killer; Bak, Bcl-2 homologous antagonist/killer; Hrk, harakiri. Diagram taken from the study by Banjara *et al* (6) with permission.

c. This inhibition blocks the activation of caspases, the key executors of apoptosis, which cleave cellular substrates and ultimately lead to cell death (58,59). Activity of Bcl-2 is regulated by its interactions with BH3-only proteins, such as Bad and Bcl-2-like protein 11, which disrupt its anti-apoptotic function under cellular stress (60). These interactions are modulated by upstream signaling pathways, including the PI3K/AKT pathway, which phosphorylates Bcl-2 to enhance its stability and anti-apoptotic function. Furthermore, Bcl-2 serves a key role in maintaining mitochondrial dynamics by influencing the balance between fission and fusion (19,61). It interacts with dynamin-related protein 1 to limit excessive mitochondrial fragmentation, a process associated with apoptotic signaling. Moreover, Bcl-2 regulates ER-mitochondria contact sites, which are key for calcium signaling and apoptotic regulation, further reinforcing its role in cell survival (62,63).

Dual role in cell survival and death. Anti-apoptotic functions of Bcl-2 are context-dependent and associated with environmental cellular stressors. Under mild stress, Bcl-2 effectively binds and neutralizes pro-apoptotic proteins such as Bax and Bak, thereby maintaining mitochondrial integrity and promoting cell survival (64,65). However, under severe or prolonged stress, Bcl-2 undergoes PTMs, such as phosphorylation or cleavage, which alter its binding affinity and disrupt its interactions with Bax and Bak (59,66). This can trigger MOMP, leading to the release of apoptogenic factors such as cytochrome c. Additionally, the function of Bcl-2 is modulated by upstream pathways, such as JNK signaling, which phosphorylate Bcl-2 at specific residues, shifting the balance from survival to apoptosis. These mechanisms highlight the dual role of Bcl-2 as a regulator of both cell survival and




Figure 2. Bcl-2 regulation in autophagy and apoptosis. Bcl-2 regulates the balance between autophagy and apoptosis by integrating cellular signals. It inhibits autophagy by binding Beclin1, preventing autophagosome formation. Under metabolic stress, AMPK activation phosphorylates Bcl-2, inhibiting its interaction with Beclin 1 and promoting autophagy. mTOR activation stabilizes Bcl-2, suppressing autophagy. Bcl-2 modulates mitophagy by regulating PINK1 and Parkin, ensuring mitochondrial quality control. In response to severe stress, MOMP triggers apoptosis, with Bcl-2 acting as a key regulator. Oxidative stress modifies Bcl-2 via post-translational modifications, influencing the shift between autophagy and apoptosis. PINK1, PTEN-induced kinase 1; MOMP, mitochondrial outer membrane permeabilization; Parkin, E3 ubiquitin ligase. This image was created with BioRender.com.

programmed cell death depending on cellular context and stress severity (67-69).

5. Interplay between autophagy and apoptosis

Molecular crosstalk. Interplay between autophagy and apoptosis involves shared regulatory proteins, including Bcl-2. By sequestering Beclin 1, Bcl-2 inhibits autophagy while promoting cell survival, thus ensuring cell resources are preserved under stress (70,71). This regulatory mechanism helps cells avoid autophagic overactivation, which leads to self-digestion and cellular demise. By contrast, when Bcl-2 binds to Bax or Bak, its anti-apoptotic function is compromised, tipping the balance toward apoptosis (72,73). This switch is triggered by upstream signals, such as JNK activation or oxidative stress, which alter the conformation of Bcl-2 and disrupt its interactions. The modulation of this crosstalk is key for maintaining cellular homeostasis, particularly under dynamic environmental conditions (72,74).

Pathological implications. In cancer, Bcl-2 upregulation leads to autophagy inhibition and resistance to apoptosis, facilitating tumor progression by enabling cancer cells to evade programmed cell death and adapt to metabolic stresses (75,76). This dysregulation contributes to therapy resistance, as cancer cells exploit Bcl-2-mediated survival pathways to withstand chemotherapeutic and radiological insult. In neurodegenerative diseases such as Alzheimer's and Parkinson's disease, impaired autophagy and increased apoptosis exacerbate neuronal




Figure 3. Regulation of Bcl-2 via PTMs. Bcl-2 is regulated by PTMs such as phosphorylation, ubiquitination and caspase cleavage. Phosphorylation at Ser70 promotes autophagy by dissociating Bcl-2 from Beclin 1, while other phosphorylation sites stabilize interactions with pro-apoptotic proteins, suppressing apoptosis. Caspase cleavage converts Bcl-2 into a pro-apoptotic fragment, amplifying apoptosis. Ubiquitination controls its degradation, influencing cellular levels. PTM, post-translational modification; MOMP, mitochondrial outer membrane permeabilization; Mcl-1, Myeloid cell leukemia 1; Bak, Bcl-2 homologous antagonist/killer; Bcl-w, Bcl-2-like protein W; BFL-1, Bcl-2-related protein A1. This image was created with BioRender.com.

loss by promoting the accumulation of damaged organelles and proteins, further destabilizing cell homeostasis (77,78). Targeting Bcl-2 to restore the balance between autophagy and apoptosis holds therapeutic potential for mitigating disease progression, enhancing cell survival and improving treatment response in these conditions (19).

6. Therapeutic implications

Cancer therapy and drug resistance. Upregulation of the anti-apoptotic protein Bcl-2 (79) contributing to chemotherapy resistance in numerous types of cancer, particularly hematological malignancies such as chronic lymphocytic and acute myeloid leukemia (80). The development of Bcl-2 inhibitors, notably venetoclax, targets this resistance mechanism. Venetoclax, a selective Bcl-2 inhibitor, has efficacy in inducing apoptosis in cancer cells by antagonizing the function of Bcl-2 (81,82). Other Bcl-2 inhibitors, such as navitoclax and obatoclax, have been developed. Navitoclax targets both Bcl-2 and Bcl-xL, making it a broader inhibitor, while obatoclax is a pan-BCL inhibitor that disrupts multiple anti-apoptotic proteins (83). However, clinical applications of these inhibitors are limited due to dose-limiting toxicity, particularly thrombocytopenia associated with navitoclax (84).

Resistance to venetoclax presents a clinical challenge. Mechanisms underlying resistance include the upregulation of alternative anti-apoptotic proteins, such as Mcl-1 and Bcl-xL, which compensates for Bcl-2 inhibition, thereby sustaining cell survival (85). Additionally, acquired mutations in the Bcl-2 gene, such as the Gly101Val mutation, decrease venetoclax binding affinity and lead to therapeutic resistance (86). Recent studies have demonstrated that pathogens manipulate host cell death pathways to promote their survival and replication, highlighting the interplay between infectious agents and cell death mechanisms (87-89). Furthermore, metabolic adaptations within cancer cells may decrease their dependence on Bcl-2-mediated survival pathways, further complicating treatment outcomes (90).

To overcome venetoclax resistance, combination therapeutic strategies are under investigation. One approach involves the concurrent inhibition of both Bcl-2 and Mcl-1 to prevent compensatory survival signaling (91). Preclinical studies have shown that combining venetoclax with Mcl-1 inhibitors enhances apoptotic responses in resistant cancer models (92,93). For example, the combination of venetoclax + Mcl-1 inhibitors, such as S63845 and AZD5991, exerts synergistic effects in preclinical leukemia models, leading to increased cancer cell apoptosis (94,95). Another promising

therapeutic strategy involves the integration of venetoclax, a potent Bcl-2 inhibitor, with autophagy modulators to counteract resistance mechanisms in cancer therapy (96). Autophagy, a catabolic process responsible for degrading and recycling intracellular components, is upregulated in malignant cells as a cytoprotective response to therapeutic stress (97). This adaptive mechanism enables tumor cells to survive apoptotic triggers induced by agents such as venetoclax (98).

Furthermore, dual inhibition strategies targeting both Bcl-2 and autophagy-associated signaling pathways, including the PI3K/Akt/mTOR axis, have garnered interest (99). The combination of venetoclax with PI3K inhibitors (e.g., idelalisib) or mTOR inhibitors (e.g., everolimus) has shown synergistic cytotoxicity in hematologic malignancies by concurrently blocking parallel survival pathways and enhancing apoptotic priming (100). Autophagy, a cellular degradation process, is co-opted by cancer cells as a survival mechanism under therapeutic stress (101). Inhibiting autophagy in conjunction with Bcl-2 antagonism has shown promise in preclinical settings, suggesting a potential method to mitigate resistance (102). Additionally, the combination of venetoclax + PI3K/mTOR pathway inhibitors, such as idelalisib and everolimus, has been explored to enhance apoptotic responses by disrupting alternative survival signals (103). These combination approaches aim to address the adaptive resistance mechanisms that cancer cells employ to evade venetoclax-induced apoptosis.

Neurodegenerative disorder. In neurodegenerative diseases such as Alzheimer's and Parkinson's disease, dysregulation of Bcl-2 family proteins is implicated in neuronal cell death (104). Alterations in the expression of Bcl-2 and associated proteins disrupt the balance between pro-apoptotic and anti-apoptotic signals, leading to increased neuronal vulnerability and degeneration (105). For example, decreased Bcl-2 expression or function may fail to counteract pro-apoptotic stimuli, resulting in enhanced neuronal apoptosis (66). Conversely, upregulation of anti-apoptotic Bcl-2 family members, such as Bcl-2, Bcl-xL, and Mcl-1, can inhibit key apoptotic processes, leading to the accumulation of damaged neurons. Therapeutic strategies targeting Bcl-2 family proteins have been explored to restore the balance between cell survival and death in neurodegenerative disorders (106). For example, small-molecule inhibitors of anti-apoptotic proteins such as Bcl-2 and Bcl-xL, promote the clearance of damaged neurons by enhancing apoptosis (107). Conversely, in diseases like Alzheimer's and Parkinson's, upregulation of pro-survival Bcl-2 has been investigated to prevent excessive neuronal loss and mitochondrial dysfunction (106). Modulating Bcl-2 activity to enhance neuronal survival while preventing the accumulation of dysfunctional

cells holds promise as a potential approach for mitigating neurodegeneration (108).

7. Research gaps and future directions

While progress has been made in elucidating the role of Bcl-2 in autophagy and apoptosis, several key gaps remain. First, the precise mechanisms by which the PTMs of Bcl-2, such as phosphorylation, ubiquitination and sumoylation, modulate its dual role in different cell contexts require further exploration. For example, specific PTMs may have contrasting effects on its interactions with Beclin 1 vs. pro-apoptotic proteins such as Bax and Bak.

Second, the tissue-specific roles of Bcl-2 in regulating the autophagy-apoptosis axis remain largely unexplored (109). Variations in Bcl-2 expression and its interactions with cellular machinery across tissues may provide insights into why certain diseases, such as neurodegeneration and cancer, exhibit distinct pathological profiles associated with this protein.

Third, the interplay between Bcl-2 and emerging regulatory pathways, such as non-coding RNAs (for example, microRNAs and long non-coding RNAs), presents a promising but underexplored area (110). These molecules may modulate activity of Bcl-2 indirectly, influencing autophagic and apoptotic responses (111).

Additionally, the potential for combination therapies that simultaneously target anti-apoptotic and autophagy-suppressive roles of Bcl-2 has yet to be fully realized. Preclinical models should evaluate the efficacy of dual inhibitors or combinations of Bcl-2 inhibitors with autophagy modulators in cancer, neurodegenerative disease and aging-associated conditions. Finally, advances in single-cell analysis and imaging technologies should be leveraged to study the real-time dynamics of Bcl-2 in coordinating autophagy and apoptosis at the cell and subcellular levels. Such approaches may uncover transient interactions and compartmentalized functions of Bcl-2 that are not apparent in bulk analyses.

Future research is key for developing precise, context-specific therapeutic strategies targeting Bcl-2. Future studies should identify additional PTMs of Bcl-2 that regulate its dual role and tissue-specific roles of Bcl-2 in different diseases and develop combination therapies targeting both autophagy and apoptosis.

8. Conclusion

Bcl-2 is a key regulator of the autophagy-apoptosis axis, orchestrating cellular responses to stress and maintaining homeostasis. Its dual role as an inhibitor of apoptosis and modulator of autophagy underscores its key importance in cellular fate determination. By interacting with Beclin 1, Bax, Bak and other molecular partners, Bcl-2 regulates autophagic flux and apoptotic pathways to adapt to dynamic cellular environments.

In pathological contexts, such as cancer and neurodegenerative disease, dysregulation of the functions of Bcl-2 contributes to disease progression, making it a valuable therapeutic target. Targeting Bcl-2 using inhibitors or combination therapies that modulate both autophagy and apoptosis is a promising avenue for innovative treatment strategies. Furthermore,

research on the interactions of Bcl-2 with non-coding RNAs, PTMs and tissue-specific roles has increased understanding of its full regulatory network (112).

Future therapeutic interventions should develop precise, context-specific strategies to facilitate advancements in cancer therapy and neurodegeneration management. A deeper understanding of the regulation of Bcl-2 and its interplay with other cellular pathways is key for advancing biomedical research and improving patient outcomes.

Acknowledgements

Not applicable.

Funding

Not funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

AAP conceived and designed the study, performed the literature review and wrote the manuscript. Data authentication is not applicable. The author has read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Use of artificial intelligence tools

During the preparation of this work, artificial intelligence tools were used to improve the readability and language of the manuscript or to generate images, and subsequently, the authors revised and edited the content produced by the artificial intelligence tools as necessary, taking full responsibility for the ultimate content of the present manuscript.

References

1. Zheng C, Liu T, Liu H, and Wang J: Role of BCL-2 family proteins in apoptosis and its regulation by nutrients. *Curr Protein Pept Sci* 21: 799-806, 2020.
2. D'Aguzzo S and Del Bufalo D: Inhibition of Anti-Apoptotic Bcl-2 proteins in preclinical and clinical studies: Current overview in cancer. *Cells* 9: 1287, 2020.
3. Aslam M, Kanthlal SK and Panonumm R: Peptides: A supercilious candidate for activating intrinsic apoptosis by targeting mitochondrial membrane permeability for cancer therapy. *Int J Pept Res Ther* 27: 2883-2893, 2021.

4. Wolf P, Schoeniger A and Edlich F: Pro-apoptotic complexes of BAX and BAK on the outer mitochondrial membrane. *Biochim Biophys Acta Mol Cell Res* 1869: 119317, 2022.
5. Shahar N and Larisch S: Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. *Drug Resist Updat* 52: 100712, 2020.
6. Banjara S, Suraweera CD, Hinds MG and Kvansakul M: The Bcl-2 family: ancient origins, conserved structures, and divergent mechanisms. *Biomolecules* 10: 128, 2020.
7. Wang L, Klionsky DJ and Shen HM: The emerging mechanisms and functions of microautophagy. *Nat Rev Mol Cell Biol* 24: 186-203, 2023.
8. Kumar R, Chhikara BS, Gulia K and Chhillar M: Cleaning the molecular machinery of cells via proteostasis, proteolysis and endocytosis selectively, effectively, and precisely: Intracellular self-defense and cellular perturbations. *Mol Omics* 17: 11-28, 2021.
9. Alqahtani SM, Alassiri HA, Alshahrani MSM, Alahmari NA, Alshahrani NZS, Alqahtani AA and Alqahtani AM: Cellular responses to ionizing radiation: Mechanisms of DNA repair and mutation. *JICRCR* 7: 2299-2315, 2024.
10. Bertheloot D, Latz E, and Franklin BS: Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. *Cell Mol Immunol* 18: 1106-1121, 2021.
11. Bernardi P, Gerle C, Halestrap AP, Jonas EA, Karch J, Mnatsakanyan N and Soukas AA: Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions. *Cell Death Differ* 30: 1869-1885, 2023.
12. Zhang Z, Wang Q, Zhang H, Wang S, Ma X and Wang H: Golm1 facilitates the CaO₂-DOPC-DSPE200-PEI-CsPbBr₃ QDs-induced apoptotic death of hepatocytes through the stimulation of mitochondrial autophagy and mitochondrial reactive oxygen species production through interactions with P53/Beclin-1/Bcl-2. *Chem Biol Interact* 398: 111076, 2024.
13. Zajac A, Maciejczyk A, Sumorek-Wiadro J, Filipek K, Deryto K, Langner E, Pawelec J, Wasiak M, Scibiorki M, Rzeski W, *et al*: The role of Bcl-2 and Beclin-1 complex in 'switching' between apoptosis and autophagy in human glioma cells upon LY294002 and sorafenib treatment. *Cells* 12: 2670, 2023.
14. Prerna K and Dubey VK: Beclin1-mediated interplay between autophagy and apoptosis: New understanding. *Int J Biol Macromol* 204: 258-273, 2022.
15. Rosa N, Speelman-Rooms F, Parys JB and Bultynck G: Modulation of Ca²⁺ signaling by antiapoptotic Bcl-2 versus Bcl-xL: From molecular mechanisms to relevance for cancer cell survival. *Biochim Biophys Acta Rev Cancer* 1877: 188791, 2022.
16. Saleem S: Apoptosis, autophagy, necrosis and their multi galore crosstalk in neurodegeneration. *Neuroscience* 469: 162-174, 2021.
17. Sukumaran P, Nascimento Da Conceicao V, Sun Y, Ahamad N, Saraiva LR, Selvaraj S and Singh BB: Calcium signaling regulates autophagy and apoptosis. *Cells* 10: 2125, 2021.
18. Dong X, Liang Q, Pan YZ, Wang X, Kuo YC, Chiang WC, Zhang X, Williams NS, Rizo J, Levine B and De Brabander JK: Novel Bcl-2 inhibitors selectively disrupt the autophagy-specific Bcl-2-Beclin 1 protein-protein interaction. *ACS Med Chem Lett* 13: 1510-1516, 2022.
19. Wu YP, Zhang S, Xin YF, Gu LQ, Xu XZ, Zhang CD and You ZQ: Evidence for the mechanism of Shenmai injection antagonizing doxorubicin-induced cardiotoxicity. *Phytomedicine* 88: 153597, 2021.
20. Li S, Li X, Liang H, Yu K, Zhai J, Xue M, Luo Z, Zheng C and Zhang H: SARS-CoV-2 ORF7a blocked autophagy flux by intervening in the fusion between autophagosome and lysosome to promote viral infection and pathogenesis. *J Med Virol* 95: e29200, 2023.
21. Li S, Zhang H, Li W, Zhai J, Li X and Zheng C: The role of SARS-CoV-2 ORF7a in autophagy flux disruption: implications for viral infection and pathogenesis. *Autophagy* 20: 1449-1451, 2024.
22. Kataoka T: Biological properties of the BCL-2 family protein BCL-RAMBO, which regulates apoptosis, mitochondrial fragmentation, and mitophagy. *Front Cell Dev Biol* 10: 1065702, 2022.
23. King LE, Hohorst L and García-Sáez AJ: Expanding roles of BCL-2 proteins in apoptosis execution and beyond. *J Cell Sci* 136: jcs260790, 2023.
24. Iorio R, Celenza G and Petricca S: Mitophagy: Molecular mechanisms, new concepts on parkin activation and the emerging role of AMPK/ULK1 axis. *Cells* 11: 30, 2021.
25. Moyzis AG, Lally NS, Liang W, Najor RH and Gustafsson ÅB: Mcl-1 differentially regulates autophagy in response to changes in energy status and mitochondrial damage. *Cells* 11: 1469, 2022.
26. Li YY, Qin ZH and Sheng R: The multiple roles of autophagy in neural function and diseases. *Neurosci Bull* 40: 363-382, 2024.
27. El-Wetidy MS, Ahmad R, Rady I, Helal H, Rady MI, Vaali-Mohammed MA, Al-Khayal K, Traiki TB and Abdulla MH: Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells. *Cell Stress Chaperones* 26: 473-493, 2021.
28. Redza-Dutordoir M, and Averill-Bates DA: Interactions between reactive oxygen species and autophagy: Special issue: Death mechanisms in cellular homeostasis. *Biochim Biophys Acta Mol Cell Res* 1868: 119041, 2021.
29. Shu F, Xiao H, Li QN, Ren XS, Liu ZG, Hu BW, Wang HS, Wang H and Jiang GM: Epigenetic and post-translational modifications in autophagy: Biological functions and therapeutic targets. *Signal Transduct Target Ther* 8: 32, 2023.
30. Sun X, Cao S, Mao C, Sun F, Zhang X and Song Y: Post-translational modifications of p65: State of the art. *Front Cell Dev Biol* 12: 1417502, 2024.
31. Hussar P: Apoptosis regulators bcl-2 and caspase-3. *Encyclopedia* 2: 1624-1636, 2022.
32. Green DR: The mitochondrial pathway of apoptosis part II: The BCL-2 protein family. *Cold Spring Harb Perspect Biol* 14: a041046, 2022.
33. Iksen, Witayateeraporn W, Hardianti B and Pongrakhananon V: Comprehensive review of Bcl-2 family proteins in cancer apoptosis: Therapeutic strategies and promising updates of natural bioactive compounds and small molecules. *Phytother Res* 38: 2249-2275, 2024.
34. Sharma A and Trivedi AK: Regulation of apoptosis by E3 ubiquitin ligases in ubiquitin proteasome system. *Cell Biol Int* 44: 721-734, 2020.
35. Cui J and Placzek WJ: Post-transcriptional regulation of anti-apoptotic BCL2 family members. *Int J Mol Sci* 19: 308, 2018.
36. Bednarczyk M, Dąbrowska-Szeja N, Łętowski D, Dziegielewska-Gęsiak S, Waniczek D and Muc-Wiergoń M: Relationship between dietary nutrient intake and autophagy-related genes in obese humans: A narrative review. *Nutrients* 16: 4003, 2024.
37. Xi H, Wang S, Wang B, Hong X, Liu X, Li M, Shen R and Dong Q: The role of interaction between autophagy and apoptosis in tumorigenesis (Review). *Oncol Rep* 48: 208, 2022.
38. Jin C, Zhu M, Ye J, Song Z, Zheng C and Chen W: Autophagy: Are amino acid signals dependent on the mTORC1 pathway or independent? *Curr Issues Mol Biol* 46: 8780-8793, 2024.
39. Kma L and Baruah TJ: The interplay of ROS and the PI3K/Akt pathway in autophagy regulation. *Biotechnol Appl Biochem* 69: 248-264, 2022.
40. Patra S, Patil S, Klionsky DJ and Bhutia SK: Lysosome signaling in cell survival and programmed cell death for cellular homeostasis. *J Cell Physiol* 238: 287-305, 2023.
41. Kench U, Sologova S, Smolyarchuk E, Prassolov V and Spirin P: Pharmaceutical agents for targeting autophagy and their applications in clinics. *Pharmaceuticals (Basel)* 17: 1355, 2024.
42. Prasad V and Greber UF: The endoplasmic reticulum unfolded protein response-homeostasis, cell death and evolution in virus infections. *FEMS Microbiol Rev* 45: fuab016, 2021.
43. Morris JL, Gillet G, Prudent J and Popgeorgiev N: Bcl-2 family of proteins in the control of mitochondrial calcium signalling: An old chap with new roles. *Int J Mol Sci* 22: 3730, 2021.
44. Casas-Martinez JC, Samali A and McDonagh B: Redox regulation of UPR signalling and mitochondrial ER contact sites. *Cell Mol Life Sci* 81: 250, 2024.
45. Naim S and Kaufmann T: The multifaceted roles of the BCL-2 family member BOK. *Front Cell Dev Biol* 8: 574338, 2020.
46. Larrañaga-SanMiguel A, Bengoa-Vergniory N and Flores-Romero H: Crosstalk between mitochondria-ER contact sites and the apoptotic machinery as a novel health meter. *Trends Cell Biol* 35: 33-45, 2025.
47. Zhao S, Zhang Y, Lu X, Ding H, Han B, Song X, Miao H, Cui X, Wei S, Liu W, *et al*: CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway. *Int J Biol Sci* 17: 3608-3621, 2021.

48. Mancuso S, Mattana M, Carlisi M, Santoro M and Siragusa S: Effects of B-cell lymphoma on the immune system and immune recovery after treatment: The paradigm of targeted therapy. *Int J Mol Sci* 23: 3368, 2022.
49. Zeng H, Kong X, Zhang H, Chen Y, Cai S, Luo H and Chen P: Inhibiting DNA methylation alleviates cigarette smoke extract-induced dysregulation of Bcl-2 and endothelial apoptosis. *Tob Induc Dis* 18: 51, 2020.
50. Şimşek H, Akaras N, Gür C, Küçükler S and Kandemir FM: Beneficial effects of Chrysin on Cadmium-induced nephrotoxicity in rats: Modulating the levels of Nrf2/HO-1, RAGE/NLRP3, and Caspase-3/Bax/Bcl-2 signaling pathways. *Gene* 875: 147502, 2023.
51. Gulia S, Chandra P and Da A: The prognosis of cancer depends on the interplay of autophagy, apoptosis, and anoikis within the tumor microenvironment. *Cell Biochem Biophys* 81: 621-658, 2023.
52. Fernandes MGF, Luo JXX, Cui QL, Perlman K, Pernin F, Yaqubi M, Hall JA, Dudley R, Srour M, Couturier CP, *et al*: Age-related injury responses of human oligodendrocytes to metabolic insults: link to BCL-2 and autophagy pathways. *Commun Biol* 4: 20, 2021.
53. Tarantini S, Balasubramanian P, Delfavero J, Csipo T, Yabluchanskiy A, Kiss T, Nyúl-Tóth Á, Mukli P, Toth P, Ahire C, *et al*: Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice. *Geroscience* 43: 2427-2440, 2021.
54. Kong ASY, Maran S and Loh HS: Navigating the interplay between BCL-2 family proteins, apoptosis, and autophagy in colorectal cancer. *Advances in Cancer Biology-Metastasis* 11: 100126, 2024.
55. Yang D, He L, Ma S, Li S, Zhang Y, Hu C, Huang J, Xu Z, Tang D and Chen Z: Pharmacological targeting of Bcl-2 induces caspase 3-mediated cleavage of HDAC6 and regulates the autophagy process in colorectal cancer. *Int J Mol Sci* 24: 6662, 2023.
56. Andreotti DZ, Silva JDN, Matumoto AM, Orellana AM, De Mello PS and Kawamoto EM: Effects of physical exercise on autophagy and apoptosis in aged brain: Human and animal studies. *Front Nutr* 7: 94, 2020.
57. Cao Z, Tian K, Ran Y, Zhou H, Zhou L, Ding Y and Tang X: Beclin-1: A therapeutic target at the intersection of autophagy, immunotherapy, and cancer treatment. *Front Immunol* 15: 1506426, 2024.
58. Chota A, George BP and Abrahamse H: Interactions of multi-domain pro-apoptotic and anti-apoptotic proteins in cancer cell death. *Oncotarget* 12: 1615-1626, 2021.
59. Qian S, Wei Z, Yang W, Huang J, Yang Y and Wang J: The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. *Front Oncol* 12: 985363, 2022.
60. Saddam M, Paul SK, Habib MA, Fahim MA, Mimi A, Islam S, Paul B and Helal MMU: Emerging biomarkers and potential therapeutics of the BCL-2 protein family: The apoptotic and anti-apoptotic context. *Egypt J Med Hum Genet* 25: 12, 2024.
61. Kapoor I, Bodo J, Hill BT, Hsi ED and Almasan A: Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. *Cell Death Dis* 11: 941, 2020.
62. Li Y, Guo M, Niu S, Shang M, Chang X, Sun Z, Zhang R, Shen X and Xue Y: ROS and DRP1 interactions accelerate the mitochondrial injury induced by polystyrene nanoplastics in human liver HepG2 cells. *Chem Biol Interact* 379: 110502, 2023.
63. Jenner A, Peña-Blanco A, Salvador-Gallego R, Ugarte-Urbe B, Zollo C, Ganief T, Bierlmeier J, Mund M, Lee JE, Ries J, *et al*: DRP1 interacts directly with BAX to induce its activation and apoptosis. *EMBO J* 41: e108587, 2022.
64. Radika PR, Chandrasekaran D, Mahila S and Muninathan N: Role of reactive oxygen species and apoptotic genes in bad obstetric history. *Bulletin of Pure and Applied Sciences-Zoology* 43: 917-929, 2024.
65. Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, Abbas K, Moinuddin, Hassan MI, Habib S and Islam S: Apoptosis: A comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. *Cells* 13: 1838, 2024.
66. Hartman ML and Czyz M: BCL-G: 20 years of research on a non-typical protein from the BCL-2 family. *Cell Death Differ* 30: 1437-1446, 2023.
67. Gupta R, Ambasta RK and Pravir Kumar: Autophagy and apoptosis cascade: Which is more prominent in neuronal death? *Cell Mol Life Sci* 78: 8001-8047, 2021.
68. Sitthisuk P, Innajak S, Poorahong W, Samosorn S, Dolsophon K and Watanapokasin R: Effect of acacia concinna extract on apoptosis induction associated with endoplasmic reticulum stress and modulated intracellular signaling pathway in human colon HCT116 cancer cells. *Nutrients* 16: 3764, 2024.
69. Kortam MA, Ali BM and Fathy N: The deleterious effect of stress-induced depression on rat liver: Protective role of resveratrol and dimethyl fumarate via inhibiting the MAPK/ERK/JNK pathway. *J Biochem Mol Toxicol* 35: e22627, 2021.
70. Turk M, Tatli O, Alkan HF, Ozfiliz Kilbas P, Alkurt G and Dinler Doganay G: Co-chaperone bag-1 plays a role in the autophagy-dependent cell survival through Beclin 1 interaction. *Molecules* 26: 854, 2021.
71. Abu-Baih RH, Abu-Baih DH, Abdel-Hafez SMN and Fathy M: Activation of SIRT1/Nrf2/HO-1 and Beclin-1/AMPK/mTOR autophagy pathways by eprosartan ameliorates testicular dysfunction induced by testicular torsion in rats. *Sci Rep* 14: 12566, 2024.
72. Rosa N, Ivanova H, Wagner LE II, Kale J, La Rovere R, Welkenhuyzen K, Louros N, Karamanou S, Shabardina V, Lemmens I, *et al*: Bcl-xL acts as an inhibitor of IP₃R channels, thereby antagonizing Ca²⁺-driven apoptosis. *Cell Death Differ* 29: 788-805, 2022.
73. Cauwelier C, de Ridder I and Bultynck G: Recent advances in canonical versus non-canonical Ca²⁺-signaling-related anti-apoptotic Bcl-2 functions and prospects for cancer treatment. *Biochim Biophys Acta Mol Cell Res* 1871: 119713, 2024.
74. Sharma M: Interplay between autophagy and apoptosis in cancer: Mechanisms and therapeutic implications. In role of autophagy and reactive oxygen species in cancer treatment: Principles and Current Strategies 235-254, 2024.
75. Yu Y, Liu B, Li X, Lu D, Yang L, Chen L, Li Y, Cheng L, Lv F, Zhang P, *et al*: ATF4/CEMIP/PKCα promotes anoikis resistance by enhancing protective autophagy in prostate cancer cells. *Cell Death Dis* 13: 46, 2022.
76. Usman RM, Razzaq F, Akbar A, Farooqui AA, Iftikhar A, Latif A, Hassan H, Zhao J, Carew JS, Nawrocki ST and Anwer F: Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. *Asia Pac J Clin Oncol* 17: 193-208, 2021.
77. Nolte EM, Joubert AM, Lafanechère L and Mercier AE: Radiosensitization of breast cancer cells with a 2-methoxyestradiol analogue affects DNA damage and repair signaling in vitro. *Int J Mol Sci* 24: 3592, 2023.
78. Bittencourt TL, da Silva Prata RB, de Andrade Silva BJ, de Mattos Barbosa MG, Dalcolmo MP and Pinheiro RO: Autophagy as a target for drug development of skin infection caused by mycobacteria. *Front Immunol* 12: 674241, 2021.
79. O'Neill J, Manion M, Schwartz P and Hockenbery DM: Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. *Biochim Biophys Acta* 1705: 43-51, 2004.
80. Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT and Hamerschlag N: BCL-2 as therapeutic target for hematological malignancies. *J Hematol Oncol* 11: 65, 2018.
81. Cao Q, Wu X, Zhang Q, Gong J, Chen Y, You Y, Shen J, Qiang Y and Cao G: Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: A literature review. *Front Pharmacol* 14: 1291920, 2023.
82. Vervloessem T, Kerkhofs M, La Rovere RM, Sneyers F, Parys JB and Bultynck G: Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling. *Cell Calcium* 70, 102-116, 2018.
83. Choi J, Bogenberger JM and Tibes R: Targeting apoptosis in acute myeloid leukemia: Current status and future directions of BCL-2 inhibition with venetoclax and beyond. *Targ Oncol* 15: 147-162, 2020.
84. Puglisi M, Molife LR, de Jonge MJ, Khan KH, Doorn L van Forster MD, Blanco M, Gutierrez M, Franklin C, Busman T, *et al*: A phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. *Future Oncol* 17: 2747-2758, 2021.
85. Castelli G, Pelosi E and Testa U: Emerging therapies for acute myelogenous leukemia patients targeting apoptosis and mitochondrial metabolism. *Cancers (Basel)* 11: 260, 2019.
86. Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, *et al*: Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. *Cancer Discov* 9: 342-353, 2019.

87. Wanford JJ, Hachani A and Odendall C: Reprogramming of cell death pathways by bacterial effectors as a widespread virulence strategy. *Infect Immun* 90: e0061421, 2022.
88. Zhang G, Wang J, Zhao Z, Xin T, Fan X, Shen Q, Raheem A, Lee CR, Jiang H and Ding J: Regulated necrosis, a proinflammatory cell death, potentially counteracts pathogenic infections. *Cell Death Dis* 13: 637, 2022.
89. Yuan J and Ofengeim D: A guide to cell death pathways. *Nat Rev Mol Cell Biol* 25: 379-395, 2024.
90. Gao J, Wang Q, Tang YD, Zhai J, Hu W and Zheng C: When ferroptosis meets pathogenic infections. *Trends Microbiol* 31: 468-479, 2023.
91. Jin P, Jiang J, Zhou L, Huang Z, Nice EC, Huang C and Fu L: Mitochondrial adaptation in cancer drug resistance: Prevalence, mechanisms, and management. *J Hematol Oncol* 15: 97, 2022.
92. Li Y, Lee HH, Jiang VC, Che Y, McIntosh J, Jordan A, Vargas J, Zhang T, Yan F, Simmons ME, *et al*: Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. *Cell Death Dis* 14: 714, 2023.
93. Valko Z, Megyesfalvi Z, Schwendenwein A, Lang C, Paku S, Barany N, Ferencz B, Horvath-Rozsas A, Kovacs I, Schlegl E, *et al*: Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer. *Br J Cancer* 128: 1850-1861, 2023.
94. Nwosu GO, Ross DM, Powell JA and Pitson SM: Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. *Cell Death Dis* 15: 413, 2024.
95. Tatarata QZ, Wang Z and Konopleva M: BCL-2 inhibition in acute myeloid leukemia: Resistance and combinations. *Expert Rev Hematol* 17: 935-946, 2024.
96. Cabrera-Serrano AJ, Sánchez-Maldonado JM, González-Olmedo C, Carretero-Fernández M, Díaz-Beltrán L, Gutiérrez-Bautista JF, García-Verdejo FJ, Gálvez-Montosa F, López-López JA, García-Martín P, *et al*: Crosstalk between autophagy and oxidative stress in hematological malignancies: Mechanisms, implications, and therapeutic potential. *Antioxidants* 14: 264, 2025.
97. Yoshida GJ: Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: From pathophysiology to treatment. *J Hematol Oncol* 10: 67, 2017.
98. Grant S: Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies. *Leuk Lymphoma* 59: 1292-1299, 2018.
99. Xu Z, Han X, Ou D, Liu T, Li Z, Jiang G, Liu J and Zhang J: Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. *Appl Microbiol Biotechnol* 104: 575-587, 2020.
100. Yue X, Chen Q and He J: Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. *Cancer Cell Int* 20: 524, 2020.
101. Al-Odat OS, Guirguis DA, Schmalbach NK, Yao G, Budak-Alpdogan T, Jonnalagadda SC and Pandey MK: Autophagy and apoptosis: current challenges of treatment and drug resistance in multiple myeloma. *Int J Mol Sci* 24: 644, 2022.
102. Mishra R, Zokaei Nikoo M, Veeraballi S and Singh A: Venetoclax and hypomethylating agent combination in myeloid malignancies: Mechanisms of synergy and challenges of resistance. *Int J Mol Sci* 25: 484, 2023.
103. Mowers EE, Sharifi MN and Macleod KF: Autophagy in cancer metastasis. *Oncogene* 36: 1619-1630, 2017.
104. Xu J, Dong X, Huang DC, Xu P, Zhao Q and Chen B: Current advances and future strategies for BCL-2 inhibitors: Potent weapons against cancers. *Cancers (Basel)* 15: 4957, 2023.
105. Bazhanova ED and Kozlov AA: Role of apoptosis-related proteins P53 and Bcl-2 in the pathogenesis of nervous system diseases. *J Evol Biochem Phys* 60: 1475-1489, 2024.
106. Singh R, Letai A and Sarosiek K: Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. *Nat Rev Mol Cell Biol* 20: 175-193, 2019.
107. Li M, Wang D, He J, Chen L and Li H: Bcl-XL: A multifunctional anti-apoptotic protein. *Pharmacol Res* 151: 104547, 2020.
108. Murumulla L and Challa S: Role of Apoptosis in Neurodegeneration: Therapeutic targets and strategies. In apoptosis and human health: Understanding mechanistic and therapeutic potential. Singapore: Springer Nature Singapore, pp 231-249, 2024.
109. Perrotta C, Cattaneo MG, Molteni R and De Palma C: Autophagy in the regulation of tissue differentiation and homeostasis. *Front Cell Dev Biol* 8: 602901, 2020.
110. Liu M, Jiang H and Momeni MR: Epigenetic regulation of autophagy by non-coding RNAs and exosomal non-coding RNAs in colorectal cancer: A narrative review. *Int J Biol Macromol* 273(Pt 2): 132732, 2024.
111. Lindqvist LM, Heinlein M, Huang DC and Vaux DL: Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. *Proc Natl Acad Sci USA* 111: 8512-8517, 2014.
112. He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers, therapies, and resistance in Cancer. *Int J Biol Sci* 16: 2628-2647, 2020.



Copyright © 2025 Palabiyik. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.